eXmoor Pharma

eXmoor Pharma is a specialized, integrated CDMO for the cell and gene therapy sector, distinguished by its deep roots in strategic consultancy. The company provides a comprehensive, end-to-end service model encompassing CMC consulting, process development, analytical services, and GMP manufacturing from its state-of-the-art facility in Bristol, UK. With a 70% repeat business rate and a track record of supporting over 170 clients, eXmoor positions itself as a strategic partner to de-risk development and accelerate the path to commercial viability for advanced therapies. Its integrated approach aims to bridge the gap between early-phase strategy and scalable, compliant manufacturing.

Integrated CDMO service model combining CMC consultancy, process development, analytical services, and GMP manufacturing for cell therapies, viral vectors, and RNA. Features a flexible, process-agnostic facility with Grade C clean rooms, autologous stations, 200L bioreactor scale, and fill-finish capabilities.

eXmoor competes in the fragmented but consolidating CGT CDMO space against large players like Lonza, Catalent, and Thermo Fisher Scientific, as well as pure-play CGT CDMOs like Oxford Biomedica, Genezen, and Andelyn Biosciences. Its key differentiator is the deep integration of strategic consultancy services with manufacturing, a niche not fully addressed by larger, more transactional CDMOs or smaller, manufacturing-only shops.